Lattice Announces Strategic Advisory Board

Lattice Announces Strategic Advisory Board




Lattice Announces Strategic Advisory Board

BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice” or the “Company”), an emerging leader in psilocybin research and cannabis company, today announced the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Lattice’s executive team as it continues to build and strengthen the Company’s portfolio of cannabis and psilocybin related brands and products

“We have assembled a group of outstanding individuals with exceptional track records in the cannabis field to advise Management going forward,” said Guy Cook, President and CEO of Lattice Biologics. “The Strategic Advisory Board will play an important role in providing guidance and insight to Lattice as we pursue our growth strategy. Together, we look forward to building maximum shareholder value.

Inaugural members of Lattice’s Strategic Advisory Board include:

Chris Jones – Mr. Jones is the President and Founder of CANNABIS XPRESS, which is leading a roll out of quick-service cannabis retail stores across Ontario. Prior to founding CANNABIS XPRESS, Chris was the Founder and President of an early chain of several cannabis retail stores in Ontario, and had a successful exit via a public and private share sale and also served in Corporate Development for Origin House (acquired by Cresco Labs). Chris’s varied background; in entrepreneurship, finance, retail sales, fund-raising, and retail store management, provides an excellent resource for Lattice’s growth strategy. “I’m excited to be part of Lattice’s new venture, and look forward to working with Guy and the rest of the team,” said Chris Jones, President of CANNABIS XPRESS.

Ian Kerwin – Mr. Kerwin is a founder of Thrive California Industries; the sole owner of an Operating Cannabis Manufacturer and Distributor in California. He is the Chief Operating Officer and co-founder of Canadian Hemp Coalition; Industrial Hemp growers and processors. He was instrumental in the growth and cultivation of over 6000 acres of Industrial Hemp in Canada for extraction and processing.

Mr. Kerwin has a background in engineering, construction, manufacturing and design for healthcare and cannabis, he has been instrumental in raising millions for and building of many licensed operations globally.

Additionally, he has successfully executed applications, designs and construction for Health Canada regulated Psilocybin research and Dealer licenses.

“I’m excited to explore the new horizons with Lattice and to enhance the company’s vision into multi-state Cannabis and Psilocybin markets.”

Danielle O’Beirne– Danielle is a strategy and sales executive with experience in pharmaceuticals and regulated health and wellness sectors. She has successfully brought over 200 products and services to market for over a dozen companies and recently launched one of the most successful Cannabis 2.0 portfolios across Canada. Previously, Danielle spent several years at Shoppers Drug Mart, playing a key role on the cannabis and health and wellness strategy team. She also gained pharmaceutical marketing experience from her time at GSK where she supported several blockbuster drugs.

“I look forward to supporting the commercialization of Lattices portfolio of cannabis and psilocybin brands and products.”

About Lattice Biologics Ltd.:

Lattice Biologics is traded on the TSX-V under the symbol: LBL.

Lattice is focused on the research and commercialization of psychedelic products in combination with its stem cell based regenerative compounds to create new and patentable technologies and medicines that improve health and alleviate suffering. Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana.

Lattice Biologics is discontinuing its Biologics business which develops and manufactures biologic products to domestic and international markets. The products are used in a variety of surgical applications.

Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement on Forward-Looking Information:

Certain information contained in this news release constitutes “forward-looking statements” within the meaning of the ‘safe harbour’ provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “planned”, “potential”, “future”, “expected”, “could”, “possible”, “goal”, “intends”, “will” or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company’s strategy, plans, or future financial performance, such as statements with respect to the Transaction, and other statements that express management’s expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.

United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

Subscribe to Lattice News Updates
Follow us on Twitter: @LatticeBio

Contacts

Media Contact:
Guy Cook, CEO

Lattice Biologics Ltd.

(TSX-V: LBL) (OTCBB: LBLTF)

512 E. Madison Ave. Suite#A1

Belgrade, MT 59714

480-563-0800 Office

News@LatticeBiologics.com
www.LatticeBiologics.com